γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.
复制标题

DOI:
10.1038/s41568-019-0153-5
复制
发表时间:
2019-07
期刊:
Nature reviews. Cancer
影响因子:
--
通讯作者:
Coffelt SB
Coffelt SB
中科院分区:
其他
文献类型:
--
作者:
Silva-Santos B;Mensurado S;Coffelt SB

文献摘要

参考文献

被引文献

相似文献

癌症免疫疗法的潜力依赖于动员能够产生抗肿瘤细胞因子并有效杀死肿瘤细胞的免疫细胞。这些是 γδ T 细胞的主要属性,γδ T 细胞是一种经常被低估的淋巴谱系,尽管它在肿瘤免疫监视中发挥着重要作用,并且已在多种临床前癌症模型中建立了这种作用。尽管如此,在特定情况下,肿瘤微环境似乎动员了具有免疫抑制或肿瘤促进功能的γδ T细胞,因此强调了调节γδ T细胞反应以实现其转化为有效的癌症免疫疗法的重要性。在这篇综述中,我们概述了我们对 γδ T 细胞如何参与肿瘤免疫及其功能在癌症实验模型中如何调节的理解的开创性工作和最新进展。我们还讨论了当前旨在最大化人类 γδ T 细胞治疗潜力的策略,这些策略正值人类 γδ T 细胞在癌症临床试验中进行探索的前夕,这可能使它们成为癌症免疫治疗的关键参与者。
The potential of cancer immunotherapy relies on the mobilization of immune cells capable of producing antitumour cytokines and effectively killing tumour cells. These are major attributes of γδ T cells, a lymphoid lineage that is often underestimated despite its major role in tumour immune surveillance, which has been established in a variety of preclinical cancer models. This situation notwithstanding, in particular instances the tumour microenvironment seemingly mobilizes γδ T cells with immunosuppressive or tumour-promoting functions, thus emphasizing the importance of regulating γδ T cell responses in order to realize their translation into effective cancer immunotherapies. In this Review we outline both seminal work and recent advances in our understanding of how γδ T cells participate in tumour immunity and how their functions are regulated in experimental models of cancer. We also discuss the current strategies aimed at maximizing the therapeutic potential of human γδ T cells, on the eve of their exploration in cancer clinical trials that may position them as key players in cancer immunotherapy.
DOI: 10.1158/0008-5472.can-15-0054
发表时间: 2015-09-15
期刊: Cancer research
影响因子: 11.2
作者:
Benevides L;da Fonseca DM;Donate PB;Tiezzi DG;De Carvalho DD;de Andrade JM;Martins GA;Silva JS
通讯作者: Silva JS
DOI: 10.4161/onci.22892
发表时间: 2013-01-01
期刊: Oncoimmunology
影响因子: 7.2
作者:
Correia DV;Lopes A;Silva-Santos B
通讯作者: Silva-Santos B
DOI: 10.1038/s41590-018-0161-8
发表时间: 2018-08
期刊: Nature immunology
影响因子: 30.5
作者:
Crawford G;Hayes MD;Seoane RC;Ward S;Dalessandri T;Lai C;Healy E;Kipling D;Proby C;Moyes C;Green K;Best K;Haniffa M;Botto M;Dunn-Walters D;Strid J
通讯作者: Strid J
DOI: 10.1007/s00262-011-1111-6
发表时间: 2012-03-01
影响因子: 5.8
作者:
Altvater, Bianca;Pscherer, Sibylle;Rossig, Claudia
通讯作者: Rossig, Claudia
DOI: 10.3389/fimmu.2018.01615
发表时间: 2018
影响因子: 7.3
作者:
Bhat SA;Vedpathak DM;Chiplunkar SV
通讯作者: Chiplunkar SV